The U.S. P2Y12 inhibitors market comprises products such as cangrelor, ticagrelor, and clopidogrel; which are primarily used for preventing platelet aggregation and reduce the risk of heart attacks or ischemia in patients suffering from cardiac conditions. P2Y12 inhibitors work by inhibiting the P2Y12 receptor and blocking the ADP-induced activation and aggregation of platelets. The advantages of using P2Y12 inhibitors is that they are highly effective in reducing cardiovascular risk when administered along with aspirin, have shown superior outcomes compared to clopidogrel in various clinical trials. These drugs are widely used for managing the risks associated with coronary artery disease, stroke, and other cardiac conditions.

The Global U.S. P2Y12 inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the U.S. P2Y12 inhibitors market are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation.

The market provides lucrative opportunities for players involved in developing new drug formulations, combination therapies, biomarkers for better patient stratification and management. Advancements in areas of targeted drug therapy, point of care testing, andcompanion diagnostics are expected to boost the U.S. P2Y12 inhibitors market growth during the forecast period.

Market drivers
The growth of the Global P2Y12 Inhibitors Market Share can be attributed to the rising geriatric population which is more prone to developing cardiovascular diseases. According to the United States Census Bureau, the population aged 65 years and above is projected to reach 94 million by 2060 from 56 million in 2018. The increasing prevalence of coronary artery disease, heart attacks, and strokes among the expanding aged demographic will drive the demand for P2Y12 inhibitors for preventing thrombosis during the treatment of cardiovascular conditions.

Challenges in U.S. P2Y12 Inhibitors Market
The U.S. P2Y12 inhibitors market is witnessing various challenges primarily due to the pricing pressures faced by the manufacturers and increasing generic competition. Many blockbuster drugs including Plavix, Effient and Brilinta have lost their patents and hence more companies are launching generic versions, which is significantly reducing the revenue pool of big pharmaceutical companies. Another challenge is the shift towards personalized medicine and alternative treatment options. With advances in medical research, new drugs are being developed that are more effective with fewer side effects compared to existing P2Y12 inhibitors. This is causing a decline in the usage of conventional antiplatelet drugs. Stringent regulatory norms regarding drug approval is also posing difficulties for new entrants. Overall, companies need to focus on innovation and differentiation to gain an edge over peers in this highly competitive market.

Current challenges in U.S. P2Y12 Inhibitors Market

The U.S. P2Y12 inhibitors market is facing immense challenges currently due to the Covid-19 pandemic. The outbreak has severely impacted the overall healthcare sector, disrupting both supply and demand. Non-essential medical procedures and diagnosis including cardiac treatments were postponed, thereby negatively impacting the sales of antiplatelet drugs. Lockdowns and social distancing norms also restricted the access of patients to hospitals as well as physicians. This led to reduced patient footfalls and declining prescription volumes. Additionally, supply chain disruptions and shortage of raw materials posed hindrances for manufacturers. Economic recession further weighed on the purchasing capability of consumers. To overcome these challenges, companies are leveraging telemedicine and digital platforms to continue serving patients virtually during the crisis.

SWOT Analysis
Strength: High prevalence of cardiovascular diseases in the US drives the demand. Well-established healthcare infrastructure aids market growth.
Weakness: Increasing generic competition erodes brand loyalty and prices. Shift towards alternative therapies poses threat.
Opportunity: Untapped regions still remain for market expansion. New product launches cater to unmet needs.
Threats: Stringent regulations delay approvals. Economic slowdown impacts discretionary healthcare spending.

Geographical Regions
In terms of value, North America currently dominates the U.S. P2Y12 inhibitors market and accounts for the major share. Factors such as rising unhealthy lifestyles, growing geriatric population and increasing incidence of heart attacks fuel the market in this region.

The Asia Pacific region is projected to witness the fastest growth during the forecast period. Improving healthcare infrastructure, growing medical tourism industry and rising affluence in developing nations will drive the demand of P2Y12 inhibitors in Asia Pacific region.

For more details on the report, Read- https://www.trendingwebwire.com/u-s-p2y12-inhibitors-market-trends-size-and-share-analysis/